HRD-negative high-grade carcinoma of the ovary in BRCA2 pathogenic variant carrier
Open Access
- 12 May 2024
- journal article
- research article
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 23 (2) , 139-146
Abstract
Background. Homologous recombination deficiency (HRD) is a valuable molecular marker for predicting response to platinum agents and poly(ADP-ribose)-polymerase (PARP) inhibitors. Germline and somatic alterations in the BRCA1 and BRCA2 genes are the major cause of HRD in ovarian cancer. However, in some cases, tumors arising in carriers of BRCA1 or BRCA2 pathogenic variants do not lose the normal copy of the corresponding gene and are not deficient for homologous recombination. Aim of the study was to present a case of high-grade ovarian carcinoma without HRD phenotype developed in a BRCA2 mutation carrier. Case report. A 48-year-old woman was diagnosed with multiple primaries: HER2-positive high-grade ovarian cancer and colorectal adenocarcinoma. analysis of the coding BRCA1/BRCA2 sequences revealed the germline BRCA2 c.658_659delgt [rs80359604] pathogenic variant. Given the unusual histological features, namely the absence of serous or endometrioid markers and high HER2 expression, we performed additional molecular analysis of the metastatic lesions in the lymph nodes. In all samples, the pattern of chromosomal instability did not match the HRD profile and there was loss of the mutant copy of the BRCA2 gene. Therefore, this tumor lacked the BRCAness phenotype. Conclusion. Tumors arising in HRR gene mutation carriers require additional molecular analysis for a comprehensive assessment of HRD.Keywords
This publication has 20 references indexed in Scilit:
- Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomasLaboratory Investigation, 2022
- Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)npj Precision Oncology, 2022
- Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patientsCancer Chemotherapy and Pharmacology, 2021
- BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriersNature Communications, 2017
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialThe Lancet Oncology, 2017
- Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutationsBreast Cancer Research and Treatment, 2014
- The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort studyGynecologic Oncology, 2013
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 InactivationCancer Research, 2012
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerBritish Journal of Cancer, 2012
- DNA interstrand crosslink repair and cancerNature Reviews Cancer, 2011